Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

NEU 2000

Drug Profile

NEU 2000

Alternative Names: Neu2000; Neu2000KL

Latest Information Update: 11 Mar 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Amkor Pharma
  • Developer AmKor Pharma; GNT Pharma
  • Class Benzoic acids; Neuroprotectants; Small molecules; Vascular disorder therapies
  • Mechanism of Action Antioxidants; NR2B N-Methyl-D-Aspartate antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Heart arrest; Stroke
  • Preclinical Burns
  • No development reported Myocardial infarction; Spinal cord injuries

Most Recent Events

  • 29 Nov 2018 Phase-II clinical trials in Heart arrest in South Korea (IV) (NCT03651557)
  • 05 Sep 2018 GNT Pharma plans a phase II trial for Heart Arrest in Korea (IV) (NCT03651557)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Stroke in USA (IV, Infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top